Myriad Genetics (MYGN) 8-K Filings

Myriad Genetics, Inc. detected unauthorized access within its information technology network environment on November 2, 2026. The company promptly began incident response procedures to contain the activity, investigate its scope and take remedial steps. Those steps included temporarily suspending testing operations and order management systems and resetting certain system credentials. Myriad engaged external experts to assist. Most systems have returned to normal operations, while the company continues assessing the incident, including whether patient records on systems containing patient information were accessed. As of the report, Myriad said it did not believe the incident would have a material adverse effect on its business.

Myriad Genetics reported third-quarter 2026 revenue of $202.7 million, down 1% year over year, and raised the midpoint of its full-year revenue guidance. Cancer Care Continuum and Mental Health revenue was $163.4 million, up 1%, while Prenatal Health revenue was $39.3 million, down 12%. Gross margin was 67.9%, down 200 basis points; net loss was $43.9 million versus $27.4 million a year earlier, and cash flow used in operations was $6.5 million.

On October 19, 2026, Myriad Genetics entered a definitive agreement to sell its Prenatal Health business to Labcorp for $210 million in cash, plus related inventory value at closing. The sale is subject to customary closing conditions, including regulatory approvals, and is expected to close by early 2027; the company expects it to be accretive to revenue growth and profitability upon closing. Full-year 2026 guidance is $780 million-$790 million in revenue, including $620 million-$630 million from Cancer Care Continuum and Mental Health and approximately $160 million from Prenatal Health, with adjusted gross margin of 66%-67%.

Myriad Genetics agreed to sell and assign certain assets and liabilities of its prenatal health business to Laboratory Corporation of America (Labcorp) for $210 million in cash, plus the value of the business’s inventory at closing. The business includes Foresight Carrier Screen, Prequel Prenatal Screen, FirstGene 4-in-1 Prenatal Screen and SneakPeek Early Gender Test.

Closing is subject to regulatory clearances and customary conditions, and the transaction is expected to close by early 2027. Either party may terminate if it has not closed by February 19, 2027; that date automatically extends to October 19, 2027 if regulatory clearance conditions remain unmet while all other conditions are satisfied or validly waived. Under certain circumstances, Labcorp may be required to pay Myriad a $10.5 million termination fee if failure to obtain certain regulatory clearances results in termination.

Myriad expects the transaction to be accretive to revenue growth and profitability and to strengthen its balance sheet. Labcorp expects approximately $160 million in year-one revenue, slightly accretive adjusted earnings in year one, and average diagnostics segment margins by the end of year two once fully integrated.

Myriad Genetics (MYGN) entered a separation agreement with former Chief Commercial Officer Brian Donnelly on October 6, 2026. The agreement becomes effective October 14, 2026, provided he does not revoke it before then. Donnelly’s employment ended on September 21, 2026, after his departure from the Chief Commercial Officer position effective September 16, 2026.

Under the agreement, Donnelly will receive a $1,322,294 lump-sum severance payment, among other consideration, in exchange for complying with restrictive covenants and releasing claims against the company. Certain time-based equity awards scheduled to vest within two years after the separation date will be accelerated, with annual installments deemed to vest monthly over that period. Performance-based awards remain outstanding and may vest to the extent earned if their conditions are satisfied within two years after the separation date.

Myriad Genetics, Inc. (MYGN) reported leadership changes in its commercial organization and reaffirmed its previously announced 2026 financial guidance. Effective September 16, 2026, Brian Donnelly ceased serving as Chief Commercial Officer and is expected to remain as a non-executive employee through September 21, 2026 to help transition his responsibilities.

The board appointed Vishal Sikri, formerly Senior Vice President, Product, as Executive Vice President, Commercial, effective September 16, 2026. Myriad highlighted Sikri’s molecular diagnostics and oncology experience and stated that it is reaffirming its full-year 2026 financial guidance announced on July 30, 2026.

Myriad Genetics, Inc. reported second quarter 2026 revenue of $190.7 million, an 11% decline year-over-year, as total test volumes were essentially flat at 379,000 but average revenue per test fell 9%, including an $11.0 million revenue reduction from updated collection estimates. Gross margin was 66.6%, down 460 basis points from the prior-year quarter, and operating loss was $38.9 million. Net loss was $43.2 million, or $0.46 per share. Adjusted EBITDA was $(16.9) million.

Cancer Care Continuum revenue was $114.1 million with 6% volume growth, Prenatal Health revenue was $39.8 million, down 16%, and Mental Health revenue was $36.8 million, down 3%. The company highlighted launches and expansions including Prolaris + AI and broader Precise MRD usage, and submitted Precise MRD breast for MolDX Medicare coverage. Cash and cash equivalents were $115.2 million with long-term debt of $120.7 million. For full-year 2026, Myriad now guides revenue to $770–$790 million and Adjusted Gross Margin to 66–67%, and has suspended prior Adjusted EBITDA guidance while implementing its Ascend efficiency initiative and broader strategic review.

Myriad Genetics, Inc. reported that Board member Daniel M. Skovronsky, M.D., Ph.D., resigned as a director effective June 17, 2026. The company states his resignation was not due to any disagreement with Myriad Genetics or any matter related to its operations, policies, or practices.

Myriad Genetics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the Amended and Restated 2012 Employee Stock Purchase Plan, increasing the shares authorized for issuance under the plan by an additional 4,000,000 shares.

They also approved the 2026 Employee, Director and Consultant Equity Incentive Plan, which provides for 6,400,000 shares of common stock plus 2,063,567 shares rolled over from the 2017 plan, for a total of 8,463,567 shares, with the reserve potentially rising to a maximum of 8,659,575 shares as prior awards lapse. Three Class III directors were elected to terms expiring at the 2029 annual meeting, Ernst & Young LLP was ratified as independent auditor for the year ending December 31, 2026, and an advisory vote approved named executive officer compensation. A quorum of 77,758,631 shares, representing approximately 82.33% of the 94,443,029 shares outstanding as of the April 8, 2026 record date, was present or represented.

Myriad Genetics reported first quarter 2026 revenue of $200.4 million, up 2% year-over-year, driven by growth in Cancer Care Continuum and Mental Health testing that offset weaker Prenatal Health demand. Total test volumes were 385,000, flat year-over-year, with mix shifting toward oncology and mental health.

The company posted a GAAP net loss of $34.1 million, or $0.36 per share, while adjusted loss per share was $0.09 and adjusted EBITDA was $(4.5) million. Management reiterated full-year 2026 guidance for revenue of $860–$880 million and adjusted EBITDA of $37–$49 million, and ended the quarter with $124.4 million in cash and cash equivalents.

Myriad Genetics reported fourth quarter 2025 revenue of $209.8 million, essentially flat year-over-year, with a GAAP net loss of $7.9 million, or $0.08 per share. On a non-GAAP basis, adjusted EPS was $0.04 and adjusted EBITDA was $14.3 million, reflecting lower operating expenses.

For full-year 2025, revenue was $824.5 million, down 2%, and the company recorded a GAAP net loss of $365.9 million, driven largely by $319.4 million of goodwill and long-lived asset impairments. Cash and cash equivalents were $149.6 million at December 31, 2025. Myriad reaffirmed 2026 guidance, targeting revenue of $860–$880 million, adjusted gross margin of 68–69%, and adjusted EBITDA of $37–$49 million, with Q1 2026 revenue expected between $200 and $203 million.

Myriad Genetics, Inc. reported preliminary operating trends for 2025 and introduced financial guidance for full year 2026. In a new press release, the company outlined early revenue figures for the quarter and year ended December 31, 2025 and shared its initial outlook for 2026.

For 2025, Myriad expects total test volumes of approximately 1.5 million, a 1% year-over-year increase. This reflects about 7% growth in hereditary cancer testing and 6% growth in mental health testing, partially offset by roughly a 4% decline in prenatal health testing. All financial figures are described as preliminary and remain subject to normal year-end accounting procedures and external audit, and the company includes standard cautionary language regarding forward-looking statements.

Myriad Genetics (MYGN) filed an 8-K/A to correct a single figure in its recent earnings materials. The company revised the amount labeled “Cash, cash equivalents, and restricted cash at beginning of the period” for the three months ended September 30, 2025 to $83.7 million, replacing $101.0 million previously shown in the Condensed Consolidated Statements of Cash Flows included with its press release.

The company states this was a clerical error and that no other changes were made to the original 8-K or the press release. A corrected press release is furnished as Exhibit 99.1 and incorporated by reference.

Myriad Genetics furnished an 8-K to announce financial results for the three months ended September 30, 2025. The detailed earnings release is provided as Exhibit 99.1, dated November 3, 2025, and is incorporated by reference.

The company included a forward-looking statements notice and specified, under General Instruction B-2, that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Myriad Genetics, Inc. finalized a Separation Agreement with former CFO Scott J. Leffler after his employment ended at the close of business on September 2, 2025. The agreement becomes effective on October 9, 2025 if not revoked and provides a lump-sum severance payment of $1,239,384 under the executive's existing Severance and Change of Control Agreement. The Company also agreed to accelerate vesting of time-based equity awards scheduled to vest within two years of the Separation Date, with annual installments treated as monthly vesting over that period. Outstanding performance-based awards remain subject to their original performance conditions and may vest if those conditions are met within two years. The separation includes customary non-compete, non-solicitation, and non-disparagement covenants and a release of claims.

Myriad Genetics reported that Natalie Munk, its Senior Vice President and Chief Accounting Officer, notified the company on September 29, 2025 that she will resign effective October 24, 2025. The filing states her departure is not the result of any disagreement with the company on operations, policies or practices. To maintain accounting leadership, the Board designated Benjamin R. Wheeler, the company’s Chief Financial Officer since August 2025, to serve additionally as principal accounting officer upon Ms. Munk’s departure. The filing notes Mr. Wheeler has worked at Myriad for over a decade, is a CPA, holds accounting degrees from Brigham Young University, and received no additional compensation for the designation.

Myriad Genetics (MYGN) announced a change in its finance leadership: Scott J. Leffler ceased serving as Chief Financial Officer effective August 15, 2025, and Ben R. Wheeler was appointed CFO effective August 16, 2025. Mr. Wheeler, a 13-year company veteran and CPA, previously held senior finance roles including SVP, Chief Financial Officer, Operations, and SVP, Finance and Treasury. His employment agreement sets an annual base salary of $490,000, an annual target cash bonus of 75% of base salary, standard benefit participation, and an initial equity award totaling 120,000 restricted stock units (60,000 time-based, 60,000 performance/time-based). Mr. Leffler will remain as a non-executive employee briefly to assist the transition.